People with type 2 diabetes and obesity may benefit from treatment with tirzepatide. Tirzepatide, marketed under the brand name Mounjaro, can reduce the risk of heart attacks and hospitalizations due to infections by about one-third each compared with a conventional diabetes medication. Researchers at the Technical University of Munich (TUM) and Harvard Medical School demonstrated this using health insurance data.